Make your money go further for just 25p per day

AstraZeneca vs GlaxoSmithKline: a clear coronavirus winner?

31/07/2020 · AstraZeneca (AZN)  · GlaxoSmithKline (GSK)  · Tristel (TSTL) 

Coronavirus Pharma and Biotech UK

GSK logo

The pharmaceutical industry has enjoyed a strong 2020. These are companies which – in the eyes of investors – could really benefit from the period of immense disruption.


But financial results from the UK’s two pharma giants reveal that there is another trend in play here: focus on Covid-19 has dented demand for other, less pressing treatments. Routine GP appointments, prescriptions and subsequently pharma sales have declined in the last three months.

That was reflected in half year results at GlaxoSmithKline (LON: GSK) where an 8% like-for-like decline in sales to £7.6bn came in behind analyst estimates. Falling demand was experienced across all three…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

Have your say

Log in or register to view or add comments.

For access to the top news and insights from the investment world

REGISTER FREE

Become a Champion Investor for just £90 a year.
 
 

START FREE TRIAL

More on AstraZeneca

AstraZeneca vs GlaxoSmithKline: a clear coronavirus winner?

31/07/2020 · Company Insights

The pharmaceutical industry has enjoyed a strong 2020. These are companies which – in the eyes…


Coronavirus impact: 29 April - surging profits and depression era declines

29/04/2020 · Company Insights

One of the world’s largest companies issued impressive results but the outlook is significantly more challenging.…


More on GlaxoSmithKline

AstraZeneca vs GlaxoSmithKline: a clear coronavirus winner?

31/07/2020 · Company Insights

The pharmaceutical industry has enjoyed a strong 2020. These are companies which – in the eyes…


UK dividends are unsustainable

28/01/2020 · Your Money

A whopping £12bn was returned to UK shareholders in the form of special dividends in 2019.…


More on Tristel

AstraZeneca vs GlaxoSmithKline: a clear coronavirus winner?

31/07/2020 · Company Insights

The pharmaceutical industry has enjoyed a strong 2020. These are companies which – in the eyes…


Coronavirus impact: 22 July part 2 - pandemic winner offers overly cautious outlook

22/07/2020 · Company Insights

Shareholders have been taking profit from beneficiaries of the pandemic and there are concerns of a more challenging…


More Company Insights

July 2020: AIM arrivals and departures

Survivors of the automotive slump: Tesla and who else?

07/08/2020 · AB Dynamics · Alphabet · Tesla